A new set of recommendations for health care workers on the front lines, to help them make decisions on how to treat the most critical COVID-19 patients, those with severe lung or heart failure, has been published.
The breakthrough, which identified the location and function of every human gene, offered the promise of medical care tailored specifically to individual patients, based on their personal genetic makeup.
When researchers identified a gene associated with a 44 per cent risk of breast cancer in women, for example, it seemed that protecting them might be as simple as deactivating that gene.
But the promise of such personalized medicine has not fully materialized, say two McMaster researchers, because the full sophistication of the genetic blueprint has a more complex and far-reaching influence on human health than scientists had first realized.
Antibody found to block infection by the novel coronavirus SARS-CoV-2 in cells.
The ‘47D11’ antibody targets the ‘spike protein’ of the destructive coronavirus.
Continue reading “Antibody prevents the COVID-19 virus from infecting human cells” »
The debate is focused on a subset of gain-of-function studies that manipulate deadly viruses to increase their transmissibility or virulence. “This is what happens to viruses in the wild”, explains Carrie Wolinetz, head of the NIH Office of Science Policy. “Gain-of-function experiments allow us to understand how pandemic viruses evolve, so that we can make predictions, develop countermeasures, and do disease surveillance”. Although none of the widely publicised mishaps of 2014 involved such work, the NIH decided to suspend funding for gain-of-function studies involving influenza, MERS-CoV, and SARS-CoV.
The US moratorium on gain-of-function experiments has been rescinded, but scientists are split over the benefits—and risks—of such studies. Talha Burki reports.
On Dec 19, 2017, the US National Institutes of Health (NIH) announced that they would resume funding gain-of-function experiments involving influenza, Middle East respiratory syndrome coronavirus, and severe acute respiratory syndrome coronavirus. A moratorium had been in place since October, 2014. At the time, the NIH had stated that the moratorium “will be effective until a robust and broad deliberative process is completed that results in the adoption of a new US Government gain-of-function research policy”. This process has now concluded. It was spearheaded by the National Science Advisory Board for Biosecurity (NSABB) and led to the development of a new framework for assessing funding decisions for research involving pathogens with enhanced pandemic potential. The release of the framework by the Department of Health and Human Services (HHS), of which NIH is part, signalled the end of the funding pause.
Maria became the very first COVID-19 patient to use Stem Cell Neurotherapy for COVID-19. In about 5 days, she will began to feel the healing effects of generating new lung cells which will eliminate her breathing problems.
We repurposed some tools from the Stem Cell Therapy for Cancer/Brain Tumor. Those tools are T-Cells, B-Cells, and Natural Killer Cells. Instead of programming those cancer killing cells to attack cancer cells, we have programmed them to seek out, identify, attack, and destroy all the Coronavirus cells in the entire body.
Stem Cell Neurotherapy sends therapeutic messages, e.g., “your stem cells are transforming into new cells for the lungs, liver, and kidneys” to the DNA inside the nucleus of stem cells. Inside the nucleus, the DNA receives the message and transmits it to the RNA, which translates the message into genetic code.
NEW YORK — As Americans delay elective surgeries and avoid doctors and hospitals during the coronavirus pandemic, healthcare spending declines have more than offset the added costs of COVID-19 care, insurance executives and experts say, boosting U.S. health insurer profits.
The first study on vitamin D and COVID-19 was released as a preprint on April 23, and a second study was released as a preprint on April 26. Here’s what we can learn from the second study. The first study, which I reported on a few days ago, focused on disease severity, while the second one, which I’m reporting on here, focused on mortality.
The Results
The electronic health records of 780 laboratory-confirmed COVID-19 cases from the government hospitals of Indonesia between March 2 and April 24 was searched for data on vitamin D status prior to admission, age, sex, preexisting conditions, and mortality. Vitamin D status was classified as normal (≥30 ng/mL), insufficient (21−29 ng/mL), or deficient (≤20 ng/mL).
We are going over the latest news, as well as any breakthrough findings on the virus. In today’s updates, we’ll discuss Remdesivir, elevated risk of severe infection in men, COVID toes, UK vaccine trial as well as answer your questions from the comments below.
Numbers update
:04 Remdesivir
:10 Gender differences with COVID-19
:14 Covid Toes
:16 Rare inflammatory syndrome in children.
:18 UK Vaccine trial
:19 Pete the Cat
:20 How Are people carriers without symptoms?
:25 Could COVID-19 vaccine lead to common cold vaccine?
:27 How to clean groceries after shopping?
:29 Do postmenopausal women suffer infections as bad as men?
:32 How are people in the hospital being treated for COVID-19?
:34 How successful is plasma therapy?
:36 How is COVID-19 data being collected?
:39 Can you get reinfected after recovering from the virus?
:42 How long does immunity last (if immune at all)?
:45 Can the virus enter the body thru the eyes/ears.
MilliporeSigma and The Jenner Institute report that the Institute has begun preparations for the large-scale production of its COVID-19 vaccine candidate, ChAdOx1 nCoV-19. With patients enrolled for clinical trials for this vaccine, rapid development of the large-scale manufacturing process is a critical step in quickly and safely delivering it from the lab to patients, according to Udit Batra, CEO, MilliporeSigma.
“We have brought the future of vaccine manufacturing to the present,” said Batra. “This is an important step in treating COVID-19 and other diseases that impact global public health. This work marks a milestone in the vaccine manufacturing development journey, as clinical testing continues to advance.”
Tapping into MilliporeSigma’s previous work provided a head start for plans to scale up the manufacture of Jenner’s COVID-19 vaccine candidate, added Batra. Developing the manufacturing process itself would normally take at least six months to a year, but in just two months’ time, MilliporeSigma supported the Jenner team and their collaborators to evaluate the existing manufacturing platform for use with the new vaccine candidate, and improved critical process steps, he continued.
The study of both fermented and non-fermented soy products was based on the results of research carried out on approximately 90,000 men and women between the ages of 45 and 74 over a period of 15 years. The team calculated intake quantities for all soy products and fermented products only through a dietary survey and examined the relationship with mortality in five similarly sized groups.
Findings from a scientific study help support the long-held belief that fermented soy products like nattō are good for one’s health.
